Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2017 | Nov. 08, 2017 | |
Document and Entity Information [Abstract] | ||
Entity Registrant Name | Medizone International Inc | |
Document Type | 10-Q | |
Current Fiscal Year End Date | --12-31 | |
Entity Common Stock, Shares Outstanding | 406,517,402 | |
Amendment Flag | false | |
Entity Central Index Key | 753,772 | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Filer Category | Smaller Reporting Company | |
Entity Well-known Seasoned Issuer | No | |
Document Period End Date | Sep. 30, 2017 | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q3 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Sep. 30, 2017 | Dec. 31, 2016 | [1] |
Current assets: | |||
Cash | $ 60,521 | $ 398,290 | |
Inventory | 311,691 | 109,573 | |
Prepaid expenses | 37,722 | 81,666 | |
Total current assets | 409,934 | 589,529 | |
Other assets: | |||
Trademark and patents, net | 126,011 | 151,444 | |
Lease deposit | 2,847 | 4,272 | |
Total other assets | 128,858 | 155,716 | |
Total assets | 538,792 | 745,245 | |
LIABILITIES AND STOCKHOLDERS’ DEFICIT | |||
Accounts payable | 661,771 | 459,654 | |
Accounts payable – related parties | 19,704 | 0 | |
Accrued expenses | 622,620 | 592,621 | |
Accrued expenses – related parties | 681,044 | 538,887 | |
Other payables | 224,852 | 224,852 | |
Notes payable | 368,419 | 297,332 | |
Notes payable – related parties | 1,624,881 | 1,617,881 | |
Warrant liability | 700,512 | 985,163 | |
Total current liabilities | 4,903,803 | 4,716,390 | |
Notes payable, net of current portion | 0 | 75,000 | |
Total liabilities | 4,903,803 | 4,791,390 | |
Commitments and contingencies (Note 7) | |||
Stockholders’ deficit: | |||
Preferred stock, $0.00001 par value: 50,000,000 authorized; no shares outstanding | 0 | 0 | |
Common stock, $0.001 par value: 500,000,000 authorized; 404,517,402 and 393,934,068 shares issued and outstanding, respectively | 404,517 | 393,934 | |
Additional paid-in capital | 34,977,174 | 33,680,146 | |
Accumulated other comprehensive loss | (52,398) | (48,043) | |
Accumulated deficit | (39,694,304) | (38,072,182) | |
Total stockholders’ deficit | (4,365,011) | (4,046,145) | |
Total liabilities and stockholders’ deficit | $ 538,792 | $ 745,245 | |
[1] | The condensed consolidated balance sheet as of December 31, 2016 has been prepared using information from the audited consolidated balance sheet as of that date. |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares | Sep. 30, 2017 | Dec. 31, 2016 | [1] |
Preferred stock, shares authorized | 50,000,000 | 50,000,000 | |
Preferred stock, par value (in Dollars per share) | $ 0.00001 | $ 0.00001 | |
Preferred stock, shares outstanding | 0 | 0 | |
Common stock, shares authorized | 500,000,000 | 500,000,000 | |
Common stock, par value (in Dollars per share) | $ 0.001 | $ 0.001 | |
Common stock, shares outstanding | 404,517,402 | 393,934,068 | |
Common stock, shares issued | 404,517,402 | 393,934,068 | |
[1] | The condensed consolidated balance sheet as of December 31, 2016 has been prepared using information from the audited consolidated balance sheet as of that date. |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Revenues | $ 0 | $ 237,000 | $ 0 | $ 237,000 |
Operating Expenses: | ||||
Cost of revenues | 0 | 200,326 | 0 | 200,326 |
General and administrative | 335,326 | 363,209 | 1,603,869 | 858,455 |
Research and development | 48,226 | 75,332 | 196,932 | 343,368 |
Depreciation and amortization | 14,606 | 14,152 | 43,370 | 41,966 |
Total operating expenses | 398,158 | 653,019 | 1,844,171 | 1,444,115 |
Loss from operations | (398,158) | (416,019) | (1,844,171) | (1,207,115) |
Other income (expense): | ||||
Gain on remeasurement of warrant liability | 54,982 | 0 | 284,651 | 0 |
Interest expense | (27,079) | (8,504) | (62,627) | (25,634) |
Interest income | 6 | 2 | 25 | 66 |
Net loss | (370,249) | (424,521) | (1,622,122) | (1,232,683) |
Other comprehensive loss on foreign currency translation | (2,163) | (4,021) | (4,355) | (5,507) |
Total comprehensive loss | $ (372,412) | $ (428,542) | $ (1,626,477) | $ (1,238,190) |
Basic and diluted net loss per common share (in Dollars per share) | $ 0 | $ 0 | $ 0 | $ 0 |
Weighted average number of common shares outstanding (in Shares) | 401,673,199 | 371,151,459 | 398,041,211 | 370,333,703 |
Condensed Consolidated Stateme5
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | ||
Cash flows from operating activities: | |||
Net loss | $ (1,622,122) | $ (1,232,683) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Stock-based compensation | 807,610 | 48,000 | |
Depreciation and amortization | 43,370 | 41,966 | |
Gain on remeasurement of warrant liability | (284,651) | 0 | |
Changes in operating assets and liabilities: | |||
Inventory | (202,118) | 171,491 | |
Prepaid expenses | 82,085 | 35,815 | |
Lease deposit | 1,425 | 0 | |
Accounts payable and accounts payable – related parties | 221,821 | 49,637 | |
Accrued expenses and accrued expenses – related parties | 172,156 | 97,866 | |
Net cash used in operating activities | (780,424) | (787,908) | |
Cash flows from investing activities: | |||
Cost of registering patents | (17,936) | (17,941) | |
Net cash used in investing activities | (17,936) | (17,941) | |
Cash flows from financing activities: | |||
Principal payments on notes payable and notes payable – related parties | (35,054) | (56,534) | |
Issuance of common stock for cash | 500,000 | 160,000 | |
Net cash provided by financing activities | 464,946 | 103,466 | |
Effects of foreign currency exchange rates on cash | (4,355) | (5,507) | |
Net decrease in cash | (337,769) | (707,890) | |
Cash as of beginning of the period | 398,290 | [1] | 745,078 |
Cash as of end of the period | 60,521 | 37,188 | |
Supplemental cash flow information: | |||
Cash paid for interest | 12,549 | 8,246 | |
Settlement of accounts payable and accrued expenses with notes payable – related parties | 0 | 1,617,881 | |
Financing of insurance premiums | $ 38,141 | $ 66,755 | |
[1] | The condensed consolidated balance sheet as of December 31, 2016 has been prepared using information from the audited consolidated balance sheet as of that date. |
NOTE 1 BASIS OF PRESENTATION
NOTE 1 BASIS OF PRESENTATION | 9 Months Ended |
Sep. 30, 2017 | |
Disclosure Text Block [Abstract] | |
Business Description and Basis of Presentation [Text Block] | NOTE 1 BASIS OF PRESENTATION The financial information of Medizone International, Inc., a Nevada corporation (“Medizone), the Canadian Foundation of Global Health (“CFGH”) based in Ottawa, Canada, considered to be a variable interest entity (“VIE”) as described below, and Medizone Canada, Inc. a wholly owned subsidiary, (collectively, the “Company”), included herein is unaudited and has been prepared consistent with U.S. generally accepted accounting principles (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all information and notes required by US GAAP for complete financial statements. These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. In the opinion of management, these financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and nine months ended September 30, 2017, are not necessarily indicative of the results to be expected for the full year ending December 31, 2017. |
NOTE 2 CANADIAN FOUNDATION FOR
NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH | 9 Months Ended |
Sep. 30, 2017 | |
Disclosure Text Block [Abstract] | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH In late 2008, Medizone assisted in the formation of CFGH, a not-for-profit foundation, for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with Medizone for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for Medizone to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Medizone’s technology to as many in need as possible. Accounting standards require a VIE to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the VIE’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the VIE. In addition, a legal entity may be considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate its financial statements with those of the VIE. Medizone determined that CFGH met the requirements of a VIE effective upon the first advance to CFGH on February 12, 2009. After eliminations, the operations and equity of the non-controlling interest is not material to the consolidated financial statements. Accordingly, the financial statements of CFGH have been consolidated with Medizone for all periods presented. |
NOTE 3 BASIC AND DILUTED NET LO
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE | 9 Months Ended |
Sep. 30, 2017 | |
Earnings Per Share [Abstract] | |
Earnings Per Share [Text Block] | NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows: For the Three Months Ended September 30, 2017 2016 Numerator: Net loss $ (370,249 ) $ (424,521 ) Denominator: Weighted average number of common shares outstanding 401,673,199 371,151,459 Basic and diluted net loss per common share $ (0.00 ) $ (0.00 ) For the Nine Months Ended September 30, 2017 2016 Numerator: Net loss $ (1,622,122 ) $ (1,232,683 ) Denominator: Weighted average number of common shares outstanding 398,041,211 370,333,703 Basic and diluted net loss per common share $ (0.00 ) $ (0.00 ) Common stock equivalents, consisting of options to purchase 20,315,000 shares and warrants to purchase up to $1,000,000 of common stock, with the number of shares determined based on a 40% discount of the 20-day average stock price prior to the date of exercise, and a warrant to purchase 750,000 shares of common stock at a specified price have not been included in the calculation as their effect is antidilutive for the periods presented. |
NOTE 4 GOING CONCERN
NOTE 4 GOING CONCERN | 9 Months Ended |
Sep. 30, 2017 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Substantial Doubt about Going Concern [Text Block] | NOTE 4 GOING CONCERN The Company’s condensed consolidated financial statements are prepared assuming the Company is a going concern and contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred significant recurring losses from its inception through September 30, 2017, which have resulted in an accumulated deficit of $39,694,304 as of September 30, 2017. The Company has minimal cash, has a working capital deficit of $4,493,869, and a total stockholders’ deficit of $4,365,011 as of September 30, 2017. The Company has relied almost exclusively on debt and equity financing to sustain its operations. Accordingly, there is a substantial doubt about the Company’s ability to continue as a going concern. Continuation of the Company as a going concern is dependent upon obtaining additional capital and ultimately, upon the Company’s attaining profitable operations. The Company will require substantial additional funds to continue to develop its products, manufacture products, and fund additional losses, until revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining the necessary additional funding, it will most likely be forced to substantially reduce or cease its operations or seek protection under U.S. bankruptcy laws. The Company believes that it will need approximately $1,500,000 during the next 12 months for continued product manufacturing, research, development and marketing activities, as well as for limited general corporate purposes. During the nine months ended September 30, 2017, the Company raised gross cash proceeds totaling $500,000 through the sale of 8,333,334 shares of common stock at a price of $0.06 per share in a private offering to accredited investors, which included the Company’s Chairman and Interim CEO and an independent director. The ability of the Company to continue as a going concern is dependent on successfully accomplishing the plan described in the preceding paragraphs and eventually attaining profitable operations. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. |
NOTE 5 INVENTORY
NOTE 5 INVENTORY | 9 Months Ended |
Sep. 30, 2017 | |
Inventory Disclosure [Abstract] | |
Inventory Disclosure [Text Block] | NOTE 5 INVENTORY In December 2016, the Company terminated a Distribution and License Agreement with a distributor due to lack of market development by the distributor. In connection with the termination, the Company negotiated the return of five disinfection units on or before January 17, 2017 paying the distributor $25,000 per unit. The units were upgraded with the Company’s current technology to support the ongoing expansion of the Company’s commercial strategy. |
NOTE 6 WARRANT LIABILITY
NOTE 6 WARRANT LIABILITY | 9 Months Ended |
Sep. 30, 2017 | |
Disclosure Text Block [Abstract] | |
Derivatives and Fair Value [Text Block] | NOTE 6 WARRANT LIABILITY The Company accounts for its common stock warrants under ASC 480, Distinguishing Liabilities from Equity. In October 2016, the Company issued warrants to purchase from the Company up to $1,000,000 in common stock with the number of shares determined based on a 40% discount to the 20-day average stock price prior to the date of exercise. The warrants are exercisable between January 31, 2017 and January 30, 2018, at which point the outstanding warrants expire. Since the exercise price of the warrant is yet to be determined, the Company recorded a common stock warrant liability of $937,951 on the warrant’s issuance date and remeasured it at fair value on December 31, 2016 at $985,163. The warrant liability is remeasured at fair value at each quarter end until the warrant liability expires. The estimate was calculated using the following inputs: Input September 30, 2017 Risk-free interest rate 1.06 % Expected life 4 months Expected volatility 74.10 % Dividend yield 0.00 % Stock price $ 0.06 As of September 30, 2017, the Company recorded a decrease in the warrant liability of $284,651 resulting from the fluctuation in the Company’s stock price. The warrant liability was $700,512 as of September 30, 2017. |
NOTE 7 COMMITMENTS AND CONTINGE
NOTE 7 COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Sep. 30, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 7 COMMITMENTS AND CONTINGENCIES The Company is subject to certain claims and lawsuits arising in the normal course of business. In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or cash flows. Litigation Rakas vs. Medizone International, Inc Related Party Agreements In July 2016, the Company converted $228,109 of accounts payable – related parties, and $1,389,772 of accrued expenses – related parties into three promissory notes payable – related parties aggregating to $1,617,881. The amounts converted represent accrued expenses and accrued wages prior to 2009 owed to certain officers and executives of the Company. On February 28, 2017, the Company entered into separation and release agreements (Separation Agreements) with its former Chairman and CEO, Edwin Marshall, and its former Director of Operations, Dr. Jill Marshall. The Separation Agreements include principal payment schedules for the promissory notes issued to these individuals in 2016 as described in the previous paragraph and modify the terms of common stock option awards granted to them under the Company’s 2014 Equity Incentive Plan by increasing the exercise period of the grants from three months to three years following termination. The Company is currently in default with the terms of the promissory notes and is accruing interest at 5% per annum on the outstanding balance, with any payments made to be applied towards interest first. On March 1, 2017, the Company entered into an employment agreement with David Esposito to fill the position of Chairman and Interim CEO. The agreement stated the terms of his employment and compensation. Mr. Esposito’s compensation consisted of: (1) an annual base salary of $225,000; (2) a potential target bonus of up to 50% of base salary based on performance goals determined by the Board of Directors of the Company (“Board”); (3) equity awards, and (4) standard employee benefits, including vacation. Mr. Esposito stepped down from his position as Interim CEO upon the appointment of David Dodd as the Company’s CEO effective September 18, 2017. As of September 30, 2017, the Company has accrued wages to Mr. Esposito of $123,750. Mr. Esposito will remain as the Company’s Chairman of the Board. On September 15, 2017, the Company entered into an employment agreement with David Dodd confirming his appointment as the Company’s CEO and a member of the Board. The agreement states the terms of his employment and compensation which consists of: (1) an annual base salary of $250,000; (2) an initial target bonus of up to 65% of annual base salary based on targets established by the Board of Directors; (3) a signing bonus of 1,000,000 shares of restricted stock upon transition as CEO and an additional 1,000,000 shares of restricted stock that will best upon successful commercialization of AsepticSure in the US market; and (4) benefits as offered to other executive employees. The Company also agreed to a change of control provision that will pay severance compensation to Mr. Dodd in the event his employment is terminated by the Company without cause or by Mr. Dodd for good reason, as defined in the agreement. Other Payables As of September 30, 2017, and December 31, 2016, the Company had $224,852 of past due payables for which the Company has not received statements or demands for payment for over 19 years. Although management of the Company does not believe that the amounts will be required to be paid, the amounts are recorded as other payables until such time as the Company is certain that no liability exists and until the statute of limitations has expired. Operating Leases The Company operates a certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which provides a primary research and development platform. The lease term is June 30, 2016 through June 29, 2018, with a monthly lease payment of $3,550 Canadian Dollars plus the applicable goods and services tax. The Company has a lease arrangement for office space in Kalamazoo, Michigan. Monthly payments are approximately $1,000 and the lease expires in February of 2018. The Company previously had a month-to-month lease for office space located in California, with monthly payments of approximately $2,556. In February 2017, the Company gave 60-days’ notice that the lease would be terminated as of April 30, 2017 and has no further obligation under the lease. |
NOTE 8 EQUITY TRANSACTIONS
NOTE 8 EQUITY TRANSACTIONS | 9 Months Ended |
Sep. 30, 2017 | |
Disclosure Text Block Supplement [Abstract] | |
Shareholders' Equity and Share-based Payments [Text Block] | NOTE 8 EQUITY TRANSACTIONS Recapitalization On December 15, 2016, the Company’s stockholders approved the Board’s recommendation to increase the number of authorized shares of common stock from 395,000,000 to 500,000,000 shares in order to provide the Company with sufficient authorized shares to accomplish its objectives. The Company filed an amendment to modify its Articles of Incorporation with the State of Nevada on January 4, 2017, which was approved by the Secretary of State on January 24, 2017. Common Stock Issuances During January 2016, the Company issued 500,000 restricted shares of common stock to a consultant. The fair value of the shares on the date of grant was $48,000, or $0.096 per share. The Company recorded compensation expense of $48,000 in connection with the issuance of the shares. During May 2017, the Company issued 250,000 restricted shares of common stock to a consultant. The fair value of the shares on the date of the grant was $17,500, or $0.07 per share. The Company recorded compensation expense of $17,500 in connection with the issuance of the shares. During the nine months ended September 30, 2017, the Company issued and sold 8,333,334 restricted shares of common stock at a price of $0.06 per share to accredited investors, which included the Company’s Chairman and Interim CEO, and an independent director, for net proceeds of $500,000 as part of a private offering. The market price of the Company’s common stock on the dates of these transactions ranged from $0.06 to $0.10 per share. Common Stock Options and Awards The Company recognizes stock-based compensation expense for grants of stock option awards, stock awards, restricted stock units and restricted stock under the Company’s Incentive Plan to employees and nonemployee members of the Company’s Board of Directors. In addition, the Company grants stock options to nonemployee consultants from time to time in consideration for services performed for the Company. The Company’s 2016 Equity Incentive Award Plan (the “2016 Plan”) was approved on December 15, 2016 by the stockholders. The 2016 Plan replaces the Company’s 2008 Equity Incentive Plan (the “2008 Plan”), 2009 Incentive Stock Plan (the “2009 Plan”), 2012 Equity Incentive Award Plan (the “2012 Plan”), and the 2014 Equity Incentive Plan (the “2014 Plan” and, together with the 2008, 2009, and 2012 Plans, the “Prior Plans”). Options and awards previously granted under the Prior Plans that have not yet expired by their terms will remain outstanding until their expiration dates. Following adoption of the 2016 Plan, the Company no longer makes any grants or awards under the Prior Plans. The 2016 Plan replaces all previous plans and reserves a total of 10,000,000 shares of common stock for awards granted under the 2016 Plan. Under the 2016 Plan, as of September 30, 2017, the Company had granted options, net of forfeitures, for the purchase of a total of 6,650,000 shares, had awarded 2,000,000 shares with an additional 1,000,000 shares to be awarded upon achievement of certain performance milestones, leaving 350,00 options available for future grants or awards. The Company estimates the fair value of each stock option award by using the Black-Scholes option-pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the expected life of the options. Because the Company does not pay dividends, the dividend rate variable used in the Black-Scholes option-pricing model is zero. For the three months ended September 30, 2017 and 2016, the Company recorded stock-based compensation of $89,549 and $0, respectively. For the nine months ended September 30, 2017 and 2016, the Company recorded stock-based compensation of $807,610 and $48,000, respectively, of which $494,086, relates to options granted to employees, directors and consultants. Upon the appointment of Mr. Esposito as Interim CEO and subsequently, Mr. Dodd as CEO, the Company incurred one-time charges in aggregate of $210,000 resulting from two separate stock awards of 1,000,000 shares of common stock each. Additionally, the Company recorded a one-time charge of $89,064 relating to the modification of vesting relating to 750,000 options issued in 2014 to Mr. Esposito upon his appointment as Interim CEO. The Company also recorded a one-time charge of $14,460 of stock-based compensation expense for the modification relating to the extension of exercisability from three weeks to three years upon retirement related to Mr. Marshall and Dr. Marshall’s stock options. In June 2017, Mr. Hoyt retired from the Board and was offered the same extension of exercisability related to his options, as that was provided to Mr. Marshall and Dr. Marshall. As the stock price on the date of modification of Mr. Hoyt’s options was significantly lower than the option’s exercise price, no additional expense was recorded as the result of this modification. An additional 1,000,000 shares of common stock has been reserved as a performance award to Mr. Dodd as part of his appointment to CEO, contingent upon meeting certain performance milestones. No expense has yet been recorded in conjunction with this award as the milestones have not been met as of September 30, 2017. As of September 30, 2017, the Company had outstanding unvested options for a total of 575,000 shares with related unrecognized expense of approximately $44,000. The Company will recognize this expense over the service period or when the achievement of the required milestones becomes probable. During 2017, the Company estimated the fair value of the stock options at the date of each grant based on the following weighted average assumptions: Risk-free interest rate 1.36% to 1.99 % Expected life 5 years Expected volatility 98.38% to 101.86 % Dividend yield 0.00 % The following is a summary of the status of the Company’s outstanding options as of September 30, 2017 and changes during the nine months then ended: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value As of December 31, 2016 20,715,000 $ 0.143 2.08 $ 261,220 Granted 6,900,000 0.097 Expired and canceled (7,300,000 ) 0.206 Exercised - - As of September 30, 2017 20,315,000 0.105 3.69 - Exercisable 19,740,000 0.105 3.65 - Warrants During October 2016, the Company issued warrants to purchase up to $1,000,000 in common stock with the number of shares determined based on a 20-day average stock price prior to the date of exercise with the exercise prices discounted 40%. The warrants are exercisable between January 31, 2017 and January 30, 2018, at which point the outstanding warrants expire (see Note 6). During May 2017, the Company issued a warrant to purchase up to 750,000 shares of common stock at an exercise price of $0.10 per share to a third-party consultant. The warrant will vest when certain milestones are achieved and will expire three years from the date of issuance. |
NOTE 9 RECENT ACCOUNTING PRONOU
NOTE 9 RECENT ACCOUNTING PRONOUNCEMENTS | 9 Months Ended |
Sep. 30, 2017 | |
New Accounting Pronouncements and Changes in Accounting Principles [Abstract] | |
New Accounting Pronouncements and Changes in Accounting Principles [Text Block] | NOTE 9 RECENT ACCOUNTING PRONOUNCEMENTS In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) In February 2016, the FASB released ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting In October 2016, the FASB issued ASU No. 2016-17, Interests held Through Related Parties That are Under Common Control In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718) |
NOTE 10 SUBSEQUENT EVENTS
NOTE 10 SUBSEQUENT EVENTS | 9 Months Ended |
Sep. 30, 2017 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | NOTE 10 SUBSEQUENT EVENTS In October 2017, the Company agreed as part of a Supply and License Agreement to issue a warrant to acquire 1,000,000 shares of the Company’s common stock at $0.10 per share. The warrants are vested immediately and have a five-year term. Between October 1, 2017 and November 8, 2017, the Company sold 2,000,000 shares of common stock in a private offering to the CEO, who is considered to be an accredited investor (the “Fall 2017 Private Offering”), at a price of $0.05 per share, for gross proceeds of $100,000. |
NOTE 3 BASIC AND DILUTED NET 16
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows: For the Three Months Ended September 30, 2017 2016 Numerator: Net loss $ (370,249 ) $ (424,521 ) Denominator: Weighted average number of common shares outstanding 401,673,199 371,151,459 Basic and diluted net loss per common share $ (0.00 ) $ (0.00 ) For the Nine Months Ended September 30, 2017 2016 Numerator: Net loss $ (1,622,122 ) $ (1,232,683 ) Denominator: Weighted average number of common shares outstanding 398,041,211 370,333,703 Basic and diluted net loss per common share $ (0.00 ) $ (0.00 ) |
NOTE 6 WARRANT LIABILITY (Table
NOTE 6 WARRANT LIABILITY (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Disclosure Text Block [Abstract] | |
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] | The estimate was calculated using the following inputs: Input September 30, 2017 Risk-free interest rate 1.06 % Expected life 4 months Expected volatility 74.10 % Dividend yield 0.00 % Stock price $ 0.06 |
NOTE 8 EQUITY TRANSACTIONS (Tab
NOTE 8 EQUITY TRANSACTIONS (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Disclosure Text Block Supplement [Abstract] | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | During 2017, the Company estimated the fair value of the stock options at the date of each grant based on the following weighted average assumptions: Risk-free interest rate 1.36% to 1.99 % Expected life 5 years Expected volatility 98.38% to 101.86 % Dividend yield 0.00 % |
Share-based Compensation, Stock Options, Activity [Table Text Block] | The following is a summary of the status of the Company’s outstanding options as of September 30, 2017 and changes during the nine months then ended: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value As of December 31, 2016 20,715,000 $ 0.143 2.08 $ 261,220 Granted 6,900,000 0.097 Expired and canceled (7,300,000 ) 0.206 Exercised - - As of September 30, 2017 20,315,000 0.105 3.69 - Exercisable 19,740,000 0.105 3.65 - |
NOTE 3 BASIC AND DILUTED NET 19
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) | 9 Months Ended |
Sep. 30, 2017shares | |
Employee Stock Option [Member] | |
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) [Line Items] | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 20,315,000 |
Warrant [Member] | |
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) [Line Items] | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 750,000 |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Description | warrants to purchase up to $1,000,000 of common stock, with the number of shares determined based on a 40% discount of the 20-day average stock price prior to the date of exercise |
NOTE 3 BASIC AND DILUTED NE
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Schedule of Earnings Per Share, Basic and Diluted [Abstract] | ||||
Numerator: Net loss | $ (370,249) | $ (424,521) | $ (1,622,122) | $ (1,232,683) |
Denominator: Weighted average number of common shares outstanding | 401,673,199 | 371,151,459 | 398,041,211 | 370,333,703 |
Basic and diluted net loss per common share | $ 0 | $ 0 | $ 0 | $ 0 |
NOTE 4 GOING CONCERN (Details)
NOTE 4 GOING CONCERN (Details) - USD ($) | 9 Months Ended | ||||
Sep. 30, 2017 | May 31, 2017 | Dec. 31, 2016 | [1] | Jan. 31, 2016 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||
Retained Earnings (Accumulated Deficit) | $ (39,694,304) | $ (38,072,182) | |||
Working capital (deficit) | (4,493,869) | ||||
Stockholders' Equity Attributable to Parent | $ (4,365,011) | $ (4,046,145) | |||
Substantial Doubt about Going Concern, Conditions or Events | The Company believes that it will need approximately $1,500,000 during the next 12 months for continued product manufacturing, research, development and marketing activities, as well as for limited general corporate purposes. | ||||
Proceeds from Issuance or Sale of Equity | $ 500,000 | ||||
Stock Issued During Period, Shares, New Issues (in Shares) | 8,333,334 | ||||
Shares Issued, Price Per Share (in Dollars per share) | $ 0.06 | $ 0.07 | $ 0.096 | ||
[1] | The condensed consolidated balance sheet as of December 31, 2016 has been prepared using information from the audited consolidated balance sheet as of that date. |
NOTE 5 INVENTORY (Details)
NOTE 5 INVENTORY (Details) | 1 Months Ended |
Dec. 31, 2016USD ($) | |
Inventory Disclosure [Abstract] | |
Number of Units Returned | 5 |
Unit, Discount Rate | $ 25,000 |
NOTE 6 WARRANT LIABILITY (Detai
NOTE 6 WARRANT LIABILITY (Details) - USD ($) | Oct. 21, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | [1] |
Disclosure Text Block [Abstract] | |||||||
Warrant, Description | In October 2016, the Company issued warrants to purchase from the Company up to $1,000,000 in common stock with the number of shares determined based on a 40% discount to the 20-day average stock price prior to the date of exercise. | ||||||
Common Stock Equivalents, Value | $ 1,000,000 | ||||||
Derivative Liability, Current | $ 937,951 | $ 700,512 | $ 700,512 | $ 985,163 | |||
Derivative, Gain (Loss) on Derivative, Net | $ 54,982 | $ 0 | $ 284,651 | $ 0 | |||
[1] | The condensed consolidated balance sheet as of December 31, 2016 has been prepared using information from the audited consolidated balance sheet as of that date. |
NOTE 6 WARRANT LIABILITY (D
NOTE 6 WARRANT LIABILITY (Details) - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques | 9 Months Ended |
Sep. 30, 2017$ / shares | |
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Abstract] | |
Risk-free interest rate | 1.06% |
Expected life | 4 months |
Expected volatility | 74.10% |
Dividend yield | 0.00% |
Stock price (in Dollars per share) | $ 0.06 |
NOTE 7 COMMITMENTS AND CONTIN25
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) | Sep. 15, 2017USD ($)shares | Mar. 01, 2017USD ($) | Feb. 28, 2017 | May 08, 2002USD ($) | Jul. 31, 2016USD ($) | Sep. 30, 2017USD ($)shares | Sep. 30, 2017CADshares | Dec. 31, 2002USD ($) | Dec. 31, 2001USD ($) | Jun. 30, 2017USD ($) | Dec. 31, 2016USD ($) | |
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Accounts Payable, Current | $ 661,771 | $ 459,654 | [1] | |||||||||
Number of Notes | 3 | |||||||||||
Debt Instrument, Face Amount | $ 1,617,881 | |||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | |||||||||||
Employment Agreement, Base Salary | $ 225,000 | |||||||||||
Employment Agreement, Bonus Terms | a potential target bonus of up to 50% of base salary based on performance goals determined by the Board of Directors of the Company (“Board”) | |||||||||||
Employee-related Liabilities, Current | $ 123,750 | |||||||||||
Accounts Payable, Other, Current | $ 224,852 | 224,852 | [1] | |||||||||
Rakas Litigation [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Loss Contingency, Damages Sought, Value | $ 25,000 | |||||||||||
Ontario, Canada [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Lease Expiration Date | Jun. 29, 2018 | Jun. 29, 2018 | ||||||||||
California [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Lease Expiration Date | Apr. 30, 2017 | Apr. 30, 2017 | ||||||||||
Description of Lessee Leasing Arrangements, Operating Leases | In February 2017, the Company gave 60-days’ notice that the lease would be terminated as of April 30, 2017 and has no further obligation under the lease | In February 2017, the Company gave 60-days’ notice that the lease would be terminated as of April 30, 2017 and has no further obligation under the lease | ||||||||||
Minimum [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 3 months | |||||||||||
Maximum [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 3 years | |||||||||||
Accounts Payable- Related Party [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Debt Conversion, Converted Instrument, Amount | 228,109 | |||||||||||
Accrued Expenses - Related Parties [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 1,389,772 | |||||||||||
Settlement Amount, September 2001 [Member] | Rakas Litigation [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 25,000 | |||||||||||
Default Judgement [Member] | Rakas Litigation [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Accounts Payable, Current | $ 143,000 | 143,000 | ||||||||||
Default Judgement [Member] | Settlement Amount, January 2002 [Member] | Rakas Litigation [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Loss Contingency, Damages Sought, Value | $ 143,000 | |||||||||||
Litigation Fees [Member] | Rakas Litigation [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Accounts Payable, Current | $ 21,308 | $ 21,308 | ||||||||||
Building [Member] | Ontario, Canada [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Operating Leases, Rent Expense, Minimum Rentals | CAD | CAD 3,550 | |||||||||||
Building [Member] | Kalamazoo, Michigan [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Operating Leases, Rent Expense, Minimum Rentals | $ 1,000 | |||||||||||
Building [Member] | California [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Operating Leases, Rent Expense, Minimum Rentals | $ 2,556 | |||||||||||
Chief Executive Officer [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Employment Agreement, Base Salary | $ 250,000 | |||||||||||
Employment Agreement, Bonus Terms | an initial target bonus of up to 65% of annual base salary based on targets established by the Board of Directors | |||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | shares | 1,000,000 | 1,000,000 | ||||||||||
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche One [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | shares | 1,000,000 | |||||||||||
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche Two [Member] | ||||||||||||
NOTE 7 COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | shares | 1,000,000 | |||||||||||
[1] | The condensed consolidated balance sheet as of December 31, 2016 has been prepared using information from the audited consolidated balance sheet as of that date. |
NOTE 8 EQUITY TRANSACTIONS (Det
NOTE 8 EQUITY TRANSACTIONS (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||
May 31, 2017 | Oct. 31, 2016 | Jan. 31, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | Dec. 15, 2016 | Dec. 14, 2016 | Dec. 31, 2015 | ||
NOTE 8 EQUITY TRANSACTIONS (Details) [Line Items] | ||||||||||||
Common Stock, Shares Authorized | 500,000,000 | 500,000,000 | 500,000,000 | [1] | 500,000,000 | 395,000,000 | ||||||
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures | 500,000 | |||||||||||
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures (in Dollars) | $ 48,000 | |||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 0.07 | $ 0.096 | $ 0.06 | $ 0.06 | ||||||||
Share-based Compensation (in Dollars) | $ 17,500 | $ 48,000 | $ 807,610 | $ 48,000 | ||||||||
Stock Issued During Period, Shares, Issued for Services | 250,000 | |||||||||||
Stock Issued During Period, Value, Issued for Services (in Dollars) | $ 17,500 | |||||||||||
Stock Issued During Period, Shares, New Issues | 8,333,334 | |||||||||||
Proceeds from Issuance of Common Stock (in Dollars) | $ 500,000 | 160,000 | ||||||||||
Share Price (in Dollars per share) | $ 0.06 | $ 0.06 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 10,000,000 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | 6,650,000 | |||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 1,000,000 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 350 | 350 | ||||||||||
Allocated Share-based Compensation Expense (in Dollars) | $ 89,549 | $ 0 | $ 807,610 | $ 48,000 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 6,900,000 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 20,315,000 | 20,715,000 | ||||||||||
Class of Warrant or Rights, Granted | 750,000 | 1,000,000 | ||||||||||
Warrant, Description of Warrant | number of shares determined based on a 20-day average stock price prior to the date of exercise with the exercise prices discounted 40% | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.10 | |||||||||||
Warrant Term | 3 years | |||||||||||
Performance Milestones [Member] | ||||||||||||
NOTE 8 EQUITY TRANSACTIONS (Details) [Line Items] | ||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 2,000,000 | |||||||||||
Minimum [Member] | ||||||||||||
NOTE 8 EQUITY TRANSACTIONS (Details) [Line Items] | ||||||||||||
Share Price (in Dollars per share) | $ 0.06 | $ 0.06 | ||||||||||
Warrants, Expiration Date | January 31, 2017 | |||||||||||
Maximum [Member] | ||||||||||||
NOTE 8 EQUITY TRANSACTIONS (Details) [Line Items] | ||||||||||||
Share Price (in Dollars per share) | $ 0.10 | $ 0.10 | ||||||||||
Warrants, Expiration Date | January 30, 2018 | |||||||||||
Chief Executive Officer [Member] | ||||||||||||
NOTE 8 EQUITY TRANSACTIONS (Details) [Line Items] | ||||||||||||
Allocated Share-based Compensation Expense (in Dollars) | $ 210,000 | |||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross | 1,000,000 | |||||||||||
Chief Executive Officer [Member] | Performance Milestones [Member] | ||||||||||||
NOTE 8 EQUITY TRANSACTIONS (Details) [Line Items] | ||||||||||||
Stock Issued During Period, Shares, Share-based Compensation, Gross | 1,000,000 | |||||||||||
Chief Executive Officer [Member] | Modification of Vesting Options [Member] | ||||||||||||
NOTE 8 EQUITY TRANSACTIONS (Details) [Line Items] | ||||||||||||
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition (in Dollars) | $ 89,064 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 750,000 | |||||||||||
Chief Executive Officer [Member] | Modification of Exercisability of Options [Member] | ||||||||||||
NOTE 8 EQUITY TRANSACTIONS (Details) [Line Items] | ||||||||||||
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition (in Dollars) | $ 14,460 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 3 years | 21 days | ||||||||||
Employee Stock Option [Member] | ||||||||||||
NOTE 8 EQUITY TRANSACTIONS (Details) [Line Items] | ||||||||||||
Allocated Share-based Compensation Expense (in Dollars) | $ 494,086 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 575,000 | 575,000 | ||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | $ 44,000 | $ 44,000 | ||||||||||
[1] | The condensed consolidated balance sheet as of December 31, 2016 has been prepared using information from the audited consolidated balance sheet as of that date. |
NOTE 8 EQUITY TRANSACTIONS
NOTE 8 EQUITY TRANSACTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options | 9 Months Ended |
Sep. 30, 2017 | |
NOTE 8 EQUITY TRANSACTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items] | |
Expected life | 5 years |
Dividend yield | 0.00% |
Minimum [Member] | |
NOTE 8 EQUITY TRANSACTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items] | |
Risk-free interest rate | 1.36% |
Expected volatility | 98.38% |
Maximum [Member] | |
NOTE 8 EQUITY TRANSACTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items] | |
Risk-free interest rate | 1.99% |
Expected volatility | 101.86% |
NOTE 8 EQUITY TRANSACTION28
NOTE 8 EQUITY TRANSACTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity - USD ($) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Schedule of Share-Based Compensation, Stock Options, Activity [Abstract] | ||
Number of Shares, Balance | 20,315,000 | 20,715,000 |
Weighted Average Exercise Price, Balance | $ 0.105 | $ 0.143 |
Weighted Average Remaining Contractual Term, Balance | 3 years 251 days | 2 years 29 days |
Aggregate Intrinsic Value, Balance | $ 261,220 | |
Number of Shares, Exercisable | 19,740,000 | |
Weighted Average Exercise Price, Exercisable | $ 0.105 | |
Weighted Average Remaining Contractual Term, Exercisable | 3 years 237 days | |
Number of Shares, Granted | 6,900,000 | |
Weighted Average Exercise Price, Granted | $ 0.097 | |
Number of Shares, Expired and Canceled | (7,300,000) | |
Weighted Average Exercise Price, Expired and Canceled | $ 0.206 | |
Number of Shares, Exercised | 0 | |
Weighted Average Exercise Price, Exercised | $ 0 |
NOTE 10 SUBSEQUENT EVENTS (Deta
NOTE 10 SUBSEQUENT EVENTS (Details) - USD ($) | 1 Months Ended | 9 Months Ended | ||||
Nov. 08, 2017 | Oct. 31, 2017 | May 31, 2017 | Oct. 31, 2016 | Sep. 30, 2017 | Jan. 31, 2016 | |
NOTE 10 SUBSEQUENT EVENTS (Details) [Line Items] | ||||||
Class of Warrant or Rights, Granted | 750,000 | 1,000,000 | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.10 | |||||
Stock Issued During Period, Shares, New Issues | 8,333,334 | |||||
Shares Issued, Price Per Share | $ 0.07 | $ 0.06 | $ 0.096 | |||
Proceeds from Issuance or Sale of Equity | $ 500,000 | |||||
Subsequent Event [Member] | ||||||
NOTE 10 SUBSEQUENT EVENTS (Details) [Line Items] | ||||||
Class of Warrant or Rights, Granted | 1,000,000 | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.10 | |||||
Stock Issued During Period, Shares, New Issues | 2,000,000 | |||||
Shares Issued, Price Per Share | $ 0.05 | |||||
Proceeds from Issuance or Sale of Equity | $ 100,000 |